Back to Search Start Over

Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload

Authors :
Rui Adão
Catherine Rucker-Martin
David Montani
P. Mendes-Ferreira
Mélanie Lambert
Valérie Domergue
Véronique Capuano
Rozenn Quarck
Maria-Rosa Ghigna
Frédéric Perros
Jean-Luc Vachiery
Hélène Leribeuz
Angèle Boet
Carmen Brás-Silva
Marc Humbert
Fabrice Antigny
Quarck, Rozenn
Hôpital Bicêtre
Adhésion et Inflammation (LAI)
Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Centre Chirurgical Marie Lannelongue (CCML)
Universidade do Porto = University of Porto
Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven)
University Hospitals Leuven [Leuven]
Institut Paris Saclay d’Innovation Thérapeutique (IPSIT)
Université Paris-Sud - Paris 11 (UP11)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)
Université Paris-Saclay
Cliniques Universitaires de Bruxelles [Bruxelles, Belgique]
Antigny, Fabrice
ANR-18-CE14-0023,KAPAH,KCNK3 une nouvelle cible thérapeutique dans l'hypertension artérielle pulmonaire(2018)
Source :
Cardiovascular Research, Cardiovascular Research, 2021, 117 (12), pp.2474-2488. ⟨10.1093/cvr/cvab016⟩
Publication Year :
2021
Publisher :
Oxford University Press (OUP), 2021.

Abstract

Aims Pulmonary hypertension (PH) is a common complication of left heart disease (LHD, Group 2 PH) leading to right ventricular (RV) failure and death. Several loss-of-function (LOF) mutations in KCNK3 were identified in pulmonary arterial hypertension (PAH, Group 1 PH). Additionally, we found that KCNK3 dysfunction is a hallmark of PAH at pulmonary vascular and RV levels. However, the role of KCNK3 in the pathobiology of PH due to LHD is unknown. Methods and results We evaluated the role of KCNK3 on PH induced by ascending aortic constriction (AAC), in WT and Kcnk3-LOF-mutated rats, by echocardiography, RV catheterization, histology analyses, and molecular biology experiments. We found that Kcnk3-LOF-mutation had no consequence on the development of left ventricular (LV) compensated concentric hypertrophy in AAC, while left atrial emptying fraction was impaired in AAC-Kcnk3-mutated rats. AAC-animals (WT and Kcnk3-mutated rats) developed PH secondary to AAC and Kcnk3-mutated rats developed more severe PH than WT. AAC-Kcnk3-mutated rats developed RV and LV fibrosis in association with an increase of Col1a1 mRNA in right ventricle and left ventricle. AAC-Kcnk3-mutated rats developed severe pulmonary vascular (pulmonary artery as well as pulmonary veins) remodelling with intense peri-vascular and peri-bronchial inflammation, perivascular oedema, alveolar wall thickening, and exaggerated lung vascular cell proliferation compared to AAC-WT-rats. Finally, in lung, right ventricle, left ventricle, and left atrium of AAC-Kcnk3-mutated rats, we found a strong increased expression of Il-6 and periostin expression and a reduction of lung Ctnnd1 mRNA (coding for p120 catenin), contributing to the exaggerated pulmonary and heart remodelling and pulmonary vascular oedema in AAC-Kcnk3-mutated rats. Conclusions Our results indicate that Kcnk3-LOF is a key event in the pathobiology of PH due to AAC, suggesting that Kcnk3 channel dysfunction could play a potential key role in the development of PH due to LHD.

Details

ISSN :
00086363
Database :
OpenAIRE
Journal :
Cardiovascular Research, Cardiovascular Research, 2021, 117 (12), pp.2474-2488. ⟨10.1093/cvr/cvab016⟩
Accession number :
edsair.doi.dedup.....a241b92460cd4ef7709eedf91baf2bd8
Full Text :
https://doi.org/10.1093/cvr/cvab016⟩